Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1990 Nov;45(11):881–884. doi: 10.1136/thx.45.11.881

Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.

N Høiby 1, C Koch 1
PMCID: PMC462789  PMID: 2256020

Full text

PDF
884

Images in this article

882Image
on p.882

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auerbach H. S., Williams M., Kirkpatrick J. A., Colten H. R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985 Sep 28;2(8457):686–688. doi: 10.1016/s0140-6736(85)92929-0. [DOI] [PubMed] [Google Scholar]
  2. Costerton J. W., Cheng K. J., Geesey G. G., Ladd T. I., Nickel J. C., Dasgupta M., Marrie T. J. Bacterial biofilms in nature and disease. Annu Rev Microbiol. 1987;41:435–464. doi: 10.1146/annurev.mi.41.100187.002251. [DOI] [PubMed] [Google Scholar]
  3. Dasgupta M. K., Zuberbuhler P., Abbi A., Harley F. L., Brown N. E., Lam K., Dossetor J. B., Costerton J. W. Combined evaluation of circulating immune complexes and antibodies to Pseudomonas aeruginosa as an immunologic profile in relation to pulmonary function in cystic fibrosis. J Clin Immunol. 1987 Jan;7(1):51–58. doi: 10.1007/BF00915425. [DOI] [PubMed] [Google Scholar]
  4. Döring G., Buhl V., Høiby N., Schiøtz P. O., Botzenhart K. Detection of proteases of Pseudomonas aeruginosa in immune complexes isolated from sputum of cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand C. 1984 Oct;92(5):307–312. doi: 10.1111/j.1699-0463.1984.tb00092.x. [DOI] [PubMed] [Google Scholar]
  5. Döring G., Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun. 1983 Oct;42(1):197–201. doi: 10.1128/iai.42.1.197-201.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Döring G., Maier M., Müller E., Bibi Z., Tümmler B., Kharazmi A. Virulence factors of Pseudomonas aeruginosa. Antibiot Chemother (1971) 1987;39:136–148. doi: 10.1159/000414341. [DOI] [PubMed] [Google Scholar]
  7. Döring G., Pfestorf M., Botzenhart K., Abdallah M. A. Impact of proteases on iron uptake of Pseudomonas aeruginosa pyoverdin from transferrin and lactoferrin. Infect Immun. 1988 Jan;56(1):291–293. doi: 10.1128/iai.56.1.291-293.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Eichacker P. Q., Pinsker K., Epstein A., Schiffenbauer J., Grayzel A. Serial pulmonary function testing in patients with systemic lupus erythematosus. Chest. 1988 Jul;94(1):129–132. doi: 10.1378/chest.94.1.129. [DOI] [PubMed] [Google Scholar]
  9. Eichhorn J. H. Accuracy and comparisons in blood gas measurements. Chest. 1988 Jul;94(1):1–2. doi: 10.1378/chest.94.1.1. [DOI] [PubMed] [Google Scholar]
  10. Eichler I., Joris L., Hsu Y. P., Van Wye J., Bram R., Moss R. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. J Clin Invest. 1989 Dec;84(6):1794–1804. doi: 10.1172/JCI114364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Floris C., Sulis M. L., Bernascani M., Turno R., Tedde A., Sulis E. Pneumothorax in pleuropulmonary Kaposi's sarcoma related to acquired immunodeficiency syndrome. Am J Med. 1989 Jul;87(1):123–124. doi: 10.1016/s0002-9343(89)80504-2. [DOI] [PubMed] [Google Scholar]
  12. Goldstein W., Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis. 1986 Jul;134(1):49–56. doi: 10.1164/arrd.1986.134.1.49. [DOI] [PubMed] [Google Scholar]
  13. Govan J. R. Alginate and antibiotics. Antibiot Chemother (1971) 1989;42:88–96. doi: 10.1159/000417609. [DOI] [PubMed] [Google Scholar]
  14. Hoiby N. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Aug;82(4):541–550. [PubMed] [Google Scholar]
  15. Høiby N., Döring G., Schiøtz P. O. Pathogenic mechanisms of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. Antibiot Chemother (1971) 1987;39:60–76. [PubMed] [Google Scholar]
  16. Høiby N., Pedersen S. S. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand. 1989 May;78(3):395–404. doi: 10.1111/j.1651-2227.1989.tb11099.x. [DOI] [PubMed] [Google Scholar]
  17. Jensen T., Pedersen S. S., Høiby N., Koch C., Flensborg E. W. Use of antibiotics in cystic fibrosis. The Danish approach. Antibiot Chemother (1971) 1989;42:237–246. [PubMed] [Google Scholar]
  18. Kharazmi A. Interactions of Pseudomonas aeruginosa proteases with the cells of the immune system. Antibiot Chemother (1971) 1989;42:42–49. doi: 10.1159/000417602. [DOI] [PubMed] [Google Scholar]
  19. Langford D. T., Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results. Arch Dis Child. 1984 Dec;59(12):1131–1134. doi: 10.1136/adc.59.12.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lee K. K., Doig P., Irvin R. T., Paranchych W., Hodges R. S. Mapping the surface regions of Pseudomonas aeruginosa PAK pilin: the importance of the C-terminal region for adherence to human buccal epithelial cells. Mol Microbiol. 1989 Nov;3(11):1493–1499. doi: 10.1111/j.1365-2958.1989.tb00135.x. [DOI] [PubMed] [Google Scholar]
  21. Littlewood J. M., Miller M. G., Ghoneim A. T., Ramsden C. H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985 Apr 13;1(8433):865–865. doi: 10.1016/s0140-6736(85)92222-6. [DOI] [PubMed] [Google Scholar]
  22. Marks M. I. Antibiotic therapy for bronchopulmonary infections in cystic fibrosis. The American approach. Antibiot Chemother (1971) 1989;42:229–236. doi: 10.1159/000417624. [DOI] [PubMed] [Google Scholar]
  23. Moss R. B., Hsu Y. P., Sullivan M. M., Lewiston N. J. Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency. Pediatr Res. 1986 May;20(5):453–459. doi: 10.1203/00006450-198605000-00015. [DOI] [PubMed] [Google Scholar]
  24. Pedersen S. S., Høiby N., Shand G. H., Pressler T. Antibody response to Pseudomonas aeruginosa antigens in cystic fibrosis. Antibiot Chemother (1971) 1989;42:130–153. doi: 10.1159/000417614. [DOI] [PubMed] [Google Scholar]
  25. Pedersen S. S., Jensen T., Høiby N., Koch C., Flensborg E. W. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand. 1987 Nov;76(6):955–961. doi: 10.1111/j.1651-2227.1987.tb17271.x. [DOI] [PubMed] [Google Scholar]
  26. Petersen N. T., Høiby N., Mordhorst C. H., Lind K., Flensborg E. W., Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981 Sep;70(5):623–628. doi: 10.1111/j.1651-2227.1981.tb05757.x. [DOI] [PubMed] [Google Scholar]
  27. Pier G. B. Immunologic properties of Pseudomonas aeruginosa mucoid exopolysaccharide (alginate). Antibiot Chemother (1971) 1989;42:80–87. doi: 10.1159/000417608. [DOI] [PubMed] [Google Scholar]
  28. Plotkowski M. C., Beck G., Tournier J. M., Bernardo-Filho M., Marques E. A., Puchelle E. Adherence of Pseudomonas aeruginosa to respiratory epithelium and the effect of leucocyte elastase. J Med Microbiol. 1989 Dec;30(4):285–293. doi: 10.1099/00222615-30-4-285. [DOI] [PubMed] [Google Scholar]
  29. Schiøtz P. O. Local humoral immunity and immune reactions in the lungs of patients with cystic fibrosis. Acta Pathol Microbiol Scand Suppl. 1981;276:1–25. [PubMed] [Google Scholar]
  30. Shand G. H., Pedersen S. S., Lam K., Høiby N. Iron-regulated outer membrane proteins and virulence in Pseudomonas aeruginosa. Antibiot Chemother (1971) 1989;42:15–26. doi: 10.1159/000417599. [DOI] [PubMed] [Google Scholar]
  31. Speert D. P., Campbell M. E. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect. 1987 Jan;9(1):11–21. doi: 10.1016/0195-6701(87)90089-2. [DOI] [PubMed] [Google Scholar]
  32. Speert D. P., Lawton D., Damm S. Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J Pediatr. 1982 Aug;101(2):227–228. doi: 10.1016/s0022-3476(82)80127-3. [DOI] [PubMed] [Google Scholar]
  33. Suter S. The imbalance between granulocyte neutral proteases and antiproteases in bronchial secretions from patients with cystic fibrosis. Antibiot Chemother (1971) 1989;42:158–168. doi: 10.1159/000417616. [DOI] [PubMed] [Google Scholar]
  34. Wolz C., Kiosz G., Ogle J. W., Vasil M. L., Schaad U., Botzenhart K., Döring G. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiol Infect. 1989 Apr;102(2):205–214. doi: 10.1017/s0950268800029873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Woods D. E., To M., Sokol P. A. Pseudomonas aeruginosa exoenzyme S as a pathogenic determinant in respiratory infections. Antibiot Chemother (1971) 1989;42:27–35. doi: 10.1159/000417600. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES